The spinal muscular atrophy market comprises products used for the treatment of spinal muscular atrophy (SMA), a genetic disorder characterized by the loss of motor neurons and progressive muscle wasting. Spinal muscular atrophy causes the muscle weakness and progressive loss of movement. Key products in this market include Nusinersen and Onasemnogene abeparvovec-xioi. Nusinersen works by increasing the production of full-length SMN protein, critical for motor neuron function. Onasemnogene abeparvovec is a gene replacement therapy involving a single intravenous infusion to deliver a functional copy of SMN gene.
The Global spinal muscular atrophy market is estimated to be valued at US$ 2625 million in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024.
Key Takeaways
Key players operating in the spinal muscular atrophy market are Biogen, Novartis, Roche Holding AG.
The Spinal Muscular Atrophy Market Growth offers significant opportunities due to the approval and launch of novel gene therapies. Advances in gene editing technologies are further accelerating drug development efforts.
Technological advancements such gene therapies are driving growth in the spinal muscular atrophy market. Approval of first-ever gene therapy Onasemnogene abeparvovec has raised hopes for patients. Several other gene therapies are in pipeline which are expected to enter the market during the forecast period.
Market drivers
Increasing diagnosis rates due to newborn screening programs and rising access to therapies are driving the growth of spinal muscular atrophy market. Mandatory newborn screening programs will enable early diagnosis and timely intervention. Approval of novel gene therapies with superiority over existing therapies will further promote the uptake of spinal muscular atrophy treatment.
Current challenges in Spinal Muscular Atrophy (SMA) Market
Some of the major challenges being faced in the Spinal Muscular Atrophy Market Companies market are high treatment cost, lack of disease awareness, difficulty in early diagnosis and limited treatment options. As the available drugs are very expensive, their affordability remains a major hurdle, especially in low and middle-income countries. The symptoms of SMA are often vague in early stages making diagnosis challenging. Also, the heterogeneity in disease progression complicates clinical trials. More research is needed to develop therapies targeting different SMA subtypes and stages of the disease.
SWOT Analysis
Strength: Growing therapeutic landscape with FDA approvals of novel drugs.
Weakness: High cost of treatment remains a barrier.
Opportunity: Increasing awareness and newborn screening programs.
Threats: Long-term efficacy and safety data still needed for newer therapies.
In terms of value, North America currently holds the major share in the global SMA market owing to supportive reimbursement policies and availability of approved drugs. Europe is also among the major markets with significant patient population and government support for orphan drugs. However, Asia Pacific region is emerging as the fastest growing market due to rising healthcare investments, growing economy and expansion of key players in developing countries. Strong initiatives by patient advocacy groups and healthcare modernization will help sustain the market growth in Asia Pacific over the coming years.
The United States represents the most concentrated geographical region for SMA market in terms of value. This can be attributed to the presence of advanced healthcare infrastructure, favorable reimbursement policies, product approvals since 2017 and proactive rare disease patient community. However, China is anticipated to witness the fastest market growth during the forecast period, driven by growing genetic testing rates, rise in healthcare spending and emergence of local pharmaceutical companies.
Get more insight on Spinal Muscular Atrophy Market
Unlock More Insights—Explore the Report in the Language You Prefer
Comments on “Spinal Muscular Atrophy Market to Register 13% Growth Owing to Advancements in Gene Therapy”